Asthma
Conditions
Brief summary
This is a single patient expanded access, compassionate and non-emergency use study that provides patients with severe asthma, who do not qualify for ongoing clinical trials with dupilumab, access to this investigational treatment.
Detailed description
This study is being undertaken to determine whether dupilumab has efficacy in extremely severe asthma, and to allow a very severe asthma patient, who has been tried on nearly every immunosuppressive drug, early access to a potentially effective therapy. The patient will continue in the study indefinitely. Safety will be evaluated and serious adverse events will be reported.
Interventions
DRUGDupilumab
The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
Sponsors
Sally E. Wenzel MD
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Sever systemic corticosteroid dependent asthma for more than 5 years
Exclusion criteria
* Disease other than asthma * Circulation eosinophils more than 1500/ul * Current smoker or more than 10 pack years This is a single-patient study. The University of Pittsburgh site is not enrolling new patients.
Outcome results
None listed